Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Immutep completes enrolment for TACTI-003 Phase IIb Trial (ASX:IMM)

A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb trial evaluating efti in combination with pembrolizumab ...read more

INOVIQ - ANSEV Meeting Presentations (ASX:IIQ)

Melbourne, Australia, 8 November 2023: INOVIQ Limited (ASX:IIQ) today advises that it will present new data on the effectiveness and utility of its proprietary exosome isolation technology, EXO-NET&...read more

Immutep - Lead-in phase completed for ph2/3 trial in Breast Cancer (ASX:IMM)

-- No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients -- Good safety profile ...read more

Immutep - New Biomarker Data from TACTI-002 trial in 1st line NSCLC (ASX:IMM)

Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed...read more

Immutep Quarterly Activities Report and Appendix 4C (ASX:IMM)

Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 mon...read more

INOVIQ - Appendix 4C and Quarterly Activities Report - September 2023 (ASX:IIQ)

-- INOVIQ and Promega sign a global joint marketing agreement for INOVIQ’s EXO-NET® exosome capture technology and Promega Nucleic Acid purification systems -- INOVIQ and ResearchDx sign ...read more

icetana - Quarterly Activities Report (ASX:ICE)

icetana Limited (ASX: ICE) (“icetana” or “the Company” or “we”), an artificial intelligence software company providing solutions to detect real-time anomalous eve...read more

icetana - Quarterly Appendix 4C Cash Flow Report (ASX:ICE)

To view the report, download the attached PDF.

Immutep receives Australian R&D Tax Incentive (ASX:IMM)

SYDNEY, AUSTRALIA - Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Aust...read more

Immutep - Results of Meeting (ASX:IMM)

SYDNEY, AUSTRALIA – 24 October 2023 – Immutep Limited (ASX:IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) advises that the results of its Annual General Meeting (...read more

Immutep reports promising data from INSIGHT-003 trial (ASX:IMM)

Promising efficacy and tolerability reported from efti plus anti-PD-1 therapy and doublet chemotherapy as first line therapy in metastatic non-squamous non-small cell lung cancer con...read more

Immutep AGM 2023 - Chairman's Address (ASX:IMM)

Dear Fellow Shareholders, It’s my pleasure to welcome all our shareholders to Immutep’s Annual General Meeting 2023, a year that has seen Immutep report very encouraging clinical data...read more

Immutep AGM 2023 - CEO's Presentation (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Webcast slides for new Efti clinical data in 1st line NSCLC (ASX:IMM)

To view the presentation, download the attached PDF.

Immutep - Excellent Overall Survival in Non-Small Cell Lung Cancer (ASX:IMM)

Median Overall Survival reaches 35.5 months in first-line treatment of metastatic non-small cell lung cancer patients expressing PD-L1 (TPS >1%), 23.4 months in patients with...read more

Viewing: 91 - 105 of 200 Previous | Next